anti cancer medicine

Comprehensive Guide to Lenvat 10mg Capsules: Advanced Targeted Therapy & Global Supply In the field of oncology, Lenvat 10mg Capsules (Lenvatinib) have become a cornerstone for treating various advanced cancers. As a specialized Pharmaceutical Exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication is accessible to healthcare providers and distributors across the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, and Asia. What is Lenvat 10mg (Lenvatinib)? Lenvat contains the active ingredient Lenvatinib, a multi-receptor tyrosine kinase (RTK) inhibitor. It works by blocking specific proteins (kinases) that signal cancer cells to grow and divide. Specifically, it inhibits the Vascular Endothelial Growth Factor (VEGF) receptors, which are responsible for the development of new blood vessels that “feed“ tumors. Therapeutic Indications: What Does It Treat? Lenvat 10mg is indicated for several types of aggressive malignancies: Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. Renal Cell Carcinoma (RCC): Used in combination with Everolimus for patients with advanced kidney cancer following one prior anti-angiogenic therapy. Hepatocellular Carcinoma (HCC): First-line treatment for patients with unresectable liver cancer. Endometrial Carcinoma: Used in combination with Pembrolizumab for advanced endometrial cancer that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Product Specifications & Usage Guidelines Technical Specifications Active Ingredient: Lenvatinib (as Mesylate) Strength: 10 mg Dosage Form: Hard Capsules Manufacturer: Cipla Ltd. / Beacon Pharmaceuticals (and high-quality Indian global-export brands) Storage: Store at room temperature between 20°C to 25°C (68°F to 77°F). Keep the container tightly closed to protect from moisture. Mechanism of Action: Multi-kinase inhibitor targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET. Administration and Dosage Standard Dosing: The daily dose varies significantly depending on the type of cancer being treated. For Thyroid cancer, the typical dose is 24 mg (two 10mg and one 4mg capsule) once daily. For Liver cancer (HCC), dosing is often based on body weight (12 mg for ≥60 kg; 8 mg for <60 kg). How to Take: Capsules should be swallowed whole with water at the same time each day, with or without food. Do not crush or chew the capsules. Special Preparation: For patients unable to swallow whole capsules, Lenvat can be dissolved in a tablespoon of water or apple juice without breaking the capsule shell. Stir for 10 minutes and consume immediately. Safety Information & Common Side Effects While effective, Lenvat can cause side effects that require medical monitoring: Common: Hypertension (high blood pressure), fatigue, diarrhea, decreased appetite, and weight loss. Precautions: Patients should have their blood pressure monitored regularly. It may also affect heart and thyroid function, necessitating routine blood tests. Hand-Foot Syndrome: Some patients may experience redness or swelling on the palms of their hands or soles of their feet. Reliable Global Supply Chain by Ernest Oncology As a leading pharmaceutical exporter from India, Ernest Oncology specializes in the bulk distribution of Lenvat 10mg to Europe, the Middle East, Africa, and Asia. Cost-Effective Solutions: We provide access to high-quality Indian brands of Lenvatinib, offering significant cost savings for patients and clinics in the USA and UK. Expert Logistics: Our supply chain is optimized for speed and safety, ensuring that oncology medications reach Singapore, Sydney, or Dubai in pristine condition. Bulk Supplier Capacity: We cater to large-scale hospital orders and pharmacy distributors, providing all necessary regulatory documentation for seamless import. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

The Professional Guide to Tishtha (Nivolumab) 100mg Injection: Global Immunotherapy Supply As the global medical community adopts biosimilars for cost-effective cancer care, Tishtha (Nivolumab) 100mg Injection has emerged as a vital resource. Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) serves as a specialized pharmaceutical exporter from India, bridging the gap for advanced immunotherapy in the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia. What is Tishtha 100 mg? Tishtha is a programmed death receptor-1 (PD-1) blocking antibody. It is the world’s first biosimilar of Nivolumab, offering the same clinical efficacy as the reference biologic. By binding to the PD-1 receptor on T-cells, Tishtha prevents cancer cells from using the PD-1 pathway to hide from the immune system, effectively reactivating the body's natural defenses to destroy tumors. Comprehensive Therapeutic Indications Tishtha 100 mg is utilized in the treatment of a broad spectrum of advanced malignancies: Advanced Melanoma: As a monotherapy or in combination with other agents for unresectable or metastatic skin cancer. Non-Small Cell Lung Cancer (NSCLC): For patients who have progressed during or after platinum-based chemotherapy. Renal Cell Carcinoma (RCC): For patients with advanced kidney cancer who have received prior anti-angiogenic therapy. Classical Hodgkin Lymphoma (cHL): For patients who have relapsed or progressed after autologous stem cell transplant. Squamous Cell Carcinoma of the Head and Neck (SCCHN): For recurrent or metastatic cases. Urothelial Carcinoma: For locally advanced or metastatic bladder cancer. Product Specifications & Administration Technical Specifications Active Ingredient: Nivolumab (10 mg/mL) Strength: 100 mg / 10 mL single-dose vial Manufacturer: Zydus Lifesciences (Zydus Cadila) Form: Sterile, preservative-free, clear to opalescent, colorless to pale yellow solution. Storage: Requires strict cold-chain maintenance at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Mechanism: PD-1 Immune Checkpoint Inhibitor (Monoclonal Antibody). Clinical Usage and Dosage Administration: Tishtha must be administered as an Intravenous (IV) Infusion by a qualified healthcare professional. The infusion typically lasts 30 to 60 minutes. Dosing Schedules: Depending on the cancer type, dosing may be weight-based (e.g., 3 mg/kg) or fixed (e.g., 240 mg every 2 weeks or 480 mg every 4 weeks). Infusion Safety: Vials should be inspected for particulate matter before use. If not used immediately, the diluted solution can be stored refrigerated for up to 24 hours. Safety and Side Effects Immune-mediated adverse reactions (irAEs) are possible because the drug activates the immune system. Common: Fatigue, rash, musculoskeletal pain, and upper respiratory tract infections. Serious: Inflammation of the lungs (pneumonitis), liver (hepatitis), or colon (colitis). Patients are monitored closely for these symptoms throughout therapy. Global Distribution Excellence by Ernest Oncology Exporting high-value biologics like Tishtha 100mg requires a sophisticated logistics network. Validated Cold-Chain Logistics: We utilize specialized thermal packaging and real-time temperature tracking to ensure the 100 mg vials reach Singapore, London, or Dubai without loss of potency. Bulk Supplier Efficiency: We cater to large-scale hospital tenders and oncology distributors in South Africa, Australia, and the Middle East. Regulatory Compliance: Our team manages all export documentation and international shipping protocols, ensuring smooth customs clearance in Europe and the USA. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

The Comprehensive Guide to Darzalex 400mg (Daratumumab) Injection: Targeted Immunotherapy & Global Distribution In the advanced treatment of hematological malignancies, Darzalex 400mg Injection has emerged as a gold standard. As a leading Pharmaceutical Exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) facilitates the seamless international supply of this vital monoclonal antibody to major hubs including London, New York, Dubai, Singapore, and Johannesburg. What is Darzalex (Daratumumab)? Darzalex is a first-in-class CD38-directed monoclonal antibody. Unlike traditional chemotherapy, Darzalex specifically targets the CD38 protein, which is highly expressed on the surface of multiple myeloma cells. Mechanism of Action: Daratumumab works by binding to CD38, triggering the body’s own immune system to attack and kill the cancer cells through multiple pathways: Direct Cell Kill: Induces programmed cell death (apoptosis). Immune Recruitment: Recruits natural killer (NK) cells and macrophages to destroy the myeloma. Complement Activation: Punches holes in the cancer cell membranes. Primary Therapeutic Indications Darzalex 400mg is globally recognized for treating: Newly Diagnosed Multiple Myeloma: Often used in combination with lenalidomide, bortezomib, or dexamethasone. Relapsed or Refractory Multiple Myeloma: For patients who have received at least one to three prior therapies. Light Chain (AL) Amyloidosis: Often utilized in newly diagnosed adult patients. Product Specifications & Clinical Administration Technical Specifications Active Ingredient: Daratumumab Strength: 400 mg / 20 mL Form: Solution for Intravenous (IV) Infusion Manufacturer: Janssen / Johnson & Johnson (supplied via Ernest Oncology’s certified channels) Storage: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Keep in the original carton to protect from light. Usage and Dosage Guidelines Administration must be performed by healthcare professionals in a clinical setting equipped for infusion monitoring. Infusion Schedule: Typically given weekly for the first 8 weeks, then every two weeks up to week 24, followed by once-monthly maintenance doses. Pre-Medication: To prevent infusion-related reactions (IRRs), patients are usually given corticosteroids, antipyretics, and antihistamines prior to treatment. Blood Typing Warning: Patients must inform their doctor they are on Darzalex before blood transfusions, as the drug can interfere with blood-typing tests for up to 6 months after the last dose. Common Side Effects Infusion-related reactions (cough, wheezing, nausea). Fatigue and weakness. Upper respiratory tract infections. Decreased blood cell counts (Anemia, Neutropenia). Global Logistics by Ernest Oncology Exporting biologics like Daratumumab 400mg requires specialized expertise to maintain product efficacy across borders. Validated Cold-Chain Shipping: We utilize advanced thermal packaging to ensure Darzalex remains between 2°C and 8°C during transit to the USA, Europe, or Australia. Regulatory Compliance: We provide all necessary export documentation (COO, CoA) to ensure rapid customs clearance in the UAE, Singapore, and South Africa. Bulk Supplier Capacity: We support hospital tenders and high-volume pharmacy distributors across Africa and the Middle East. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Comprehensive Guide to Lenvat 10mg Capsules: Advanced Targeted Therapy & Global Supply In the field of oncology, Lenvat 10mg Capsules (Lenvatinib) have become a cornerstone for treating various advanced cancers. As a specialized Pharmaceutical Exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication is accessible to healthcare providers and distributors across the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, and Asia. What is Lenvat 10mg (Lenvatinib)? Lenvat contains the active ingredient Lenvatinib, a multi-receptor tyrosine kinase (RTK) inhibitor. It works by blocking specific proteins (kinases) that signal cancer cells to grow and divide. Specifically, it inhibits the Vascular Endothelial Growth Factor (VEGF) receptors, which are responsible for the development of new blood vessels that “feed“ tumors. Therapeutic Indications: What Does It Treat? Lenvat 10mg is indicated for several types of aggressive malignancies: Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. Renal Cell Carcinoma (RCC): Used in combination with Everolimus for patients with advanced kidney cancer following one prior anti-angiogenic therapy. Hepatocellular Carcinoma (HCC): First-line treatment for patients with unresectable liver cancer. Endometrial Carcinoma: Used in combination with Pembrolizumab for advanced endometrial cancer that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Product Specifications & Usage Guidelines Technical Specifications Active Ingredient: Lenvatinib (as Mesylate) Strength: 10 mg Dosage Form: Hard Capsules Manufacturer: Cipla Ltd. / Beacon Pharmaceuticals (and high-quality Indian global-export brands) Storage: Store at room temperature between 20°C to 25°C (68°F to 77°F). Keep the container tightly closed to protect from moisture. Mechanism of Action: Multi-kinase inhibitor targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET. Administration and Dosage Standard Dosing: The daily dose varies significantly depending on the type of cancer being treated. For Thyroid cancer, the typical dose is 24 mg (two 10mg and one 4mg capsule) once daily. For Liver cancer (HCC), dosing is often based on body weight (12 mg for ≥60 kg; 8 mg for <60 kg). How to Take: Capsules should be swallowed whole with water at the same time each day, with or without food. Do not crush or chew the capsules. Special Preparation: For patients unable to swallow whole capsules, Lenvat can be dissolved in a tablespoon of water or apple juice without breaking the capsule shell. Stir for 10 minutes and consume immediately. Safety Information & Common Side Effects While effective, Lenvat can cause side effects that require medical monitoring: Common: Hypertension (high blood pressure), fatigue, diarrhea, decreased appetite, and weight loss. Precautions: Patients should have their blood pressure monitored regularly. It may also affect heart and thyroid function, necessitating routine blood tests. Hand-Foot Syndrome: Some patients may experience redness or swelling on the palms of their hands or soles of their feet. Reliable Global Supply Chain by Ernest Oncology As a leading pharmaceutical exporter from India, Ernest Oncology specializes in the bulk distribution of Lenvat 10mg to Europe, the Middle East, Africa, and Asia. Cost-Effective Solutions: We provide access to high-quality Indian brands of Lenvatinib, offering significant cost savings for patients and clinics in the USA and UK. Expert Logistics: Our supply chain is optimized for speed and safety, ensuring that oncology medications reach Singapore, Sydney, or Dubai in pristine condition. Bulk Supplier Capacity: We cater to large-scale hospital orders and pharmacy distributors, providing all necessary regulatory documentation for seamless import. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tishtha (Nivolumab) 40 mg Injection: A Comprehensive Guide to Immunotherapy & Global Supply In the modern landscape of oncology, Tishtha (Nivolumab) 40 mg injection has revolutionized the treatment of multiple advanced cancers. As a specialized Pharmaceutical Exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this life-saving biosimilar is accessible to hospitals and clinics across the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, and Asia. What is Tishtha 40 mg? Tishtha is the world’s first biosimilar of Nivolumab, developed by Zydus Lifesciences. It is a programmed death receptor-1 (PD-1) blocking antibody. By inhibiting the PD-1 pathway, Tishtha helps the body's immune system recognize and attack cancer cells more effectively. Primary Therapeutic Applications Tishtha 40 mg is indicated for several types of advanced and metastatic cancers, including: Melanoma: Advanced skin cancer that has spread or cannot be removed by surgery. Non-Small Cell Lung Cancer (NSCLC): For patients whose cancer has progressed after chemotherapy. Renal Cell Carcinoma (RCC): Advanced kidney cancer. Classical Hodgkin Lymphoma: For patients who have relapsed after stem cell transplants. Head and Neck Squamous Cell Carcinoma: Recurrent or metastatic cases. Urothelial Carcinoma: Advanced bladder or urinary tract cancer. Hepatocellular Carcinoma: Liver cancer for patients previously treated with sorafenib. Product Specifications & Usage Technical Specifications Active Ingredient: Nivolumab (10 mg/mL) Dose Strength: 40 mg / 4 mL vial Formulation: Solution for Intravenous (IV) Infusion Mechanism: Monoclonal Antibody / Immune Checkpoint Inhibitor Manufacturer: Zydus Lifesciences (Zydus Cadila) Storage: Must be stored under cold-chain conditions between 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Administration and Dosage Tishtha is a parenteral medication and must be administered under the supervision of an experienced oncologist. Administration Method: It is given as an intravenous infusion over a period of 30 to 60 minutes. Dosage Schedule: The exact dose is individualized based on the patient's body weight, cancer type, and clinical response. It is often administered every 2, 3, or 4 weeks. Monitoring: Patients are closely monitored for infusion-related reactions and immune-mediated adverse reactions (IMARs) affecting the lungs, liver, or colon. Common Side Effects While highly effective, immunotherapy can cause side effects such as: Fatigue and weakness Skin rash or itching Nausea and decreased appetite Musculoskeletal pain Shortness of breath or cough Why Choose Ernest Oncology for Global Export? Ernest Oncology specializes in the bulk supply and reliable distribution of high-value oncology medications. Affordability: Tishtha offers a cost-effective alternative to the reference drug, significantly reducing the financial burden of immunotherapy. Expert Logistics: We utilize specialized validated cold-chain shipping to ensure that Tishtha 40 mg reaches Singapore, Dubai, or London with its biological integrity intact. Global Compliance: We provide all necessary documentation (CoA, COO) required for pharmaceutical imports in South Africa, Australia, and the Middle East 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Comprehensive Guide to Imbruvica (Ibrutinib) 140 mg: Global Export and Clinical Overview In the realm of hematological oncology, Imbruvica (Ibrutinib) 140 mg capsules represent a breakthrough in targeted therapy. As a specialized pharmaceutical exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication is accessible to healthcare systems and patients in London, New York, Dubai, Sydney, Singapore, and Johannesburg. What is Imbruvica (Ibrutinib) 140 mg? Imbruvica is a potent, first-in-class Bruton’s Tyrosine Kinase (BTK) Inhibitor. Unlike traditional chemotherapy, Ibrutinib is a targeted small-molecule drug that specifically blocks the BTK protein, which is essential for the signaling that allows certain B-cell cancers to grow and survive. Primary Therapeutic Indications Imbruvica is globally recognized and approved for the treatment of several B-cell malignancies and immune-related conditions: Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL): Often used as a first-line treatment or for relapsed/refractory cases, including those with 17p deletion. Waldenström’s Macroglobulinemia (WM): The only FDA-approved therapy specifically for this rare blood cancer. Chronic Graft Versus Host Disease (cGVHD): Indicated for adult and pediatric patients (age 1+) after the failure of one or more lines of systemic therapy. Mantle Cell Lymphoma (MCL) & Marginal Zone Lymphoma (MZL): Traditionally used for patients who have received at least one prior therapy. Product Specifications & Administration Specifications Active Ingredient: Ibrutinib Strength: 140 mg Dosage Form: Hard Gelatin Capsules (White, opaque, marked with “ibr 140 mg“) Mechanism: Irreversible BTK Inhibition Manufacturer: Janssen / Pharmacyclics (and high-quality Indian global-export brands) Storage: Store at 20°C to 25°C (68°F to 77°F). Maintain in original packaging to protect from moisture. Usage and Dosage Guidelines Ibrutinib therapy should be managed by a physician experienced in anticancer treatments. Standard Dosing: The daily dose varies by condition. For CLL and WM, the typical dose is 420 mg (three 140 mg capsules) taken once daily. For MCL, the dose is often 560 mg (four 140 mg capsules) daily. Method of Administration: Capsules should be swallowed whole with a glass of water at the same time each day. Do not open, break, or chew the capsules. Food Interactions: Can be taken with or without food. However, patients must avoid grapefruit juice and Seville oranges, as these can significantly increase the concentration of the drug in the blood. Missed Dose: If a dose is missed, it can be taken as soon as possible on the same day. Return to the normal schedule the following day. Do not take extra capsules to make up for a missed dose. Safety and Side Effects While generally well-tolerated compared to chemo, common side effects include: Diarrhea, fatigue, and nausea. Musculoskeletal pain and upper respiratory tract infections. Precautions: Patients should be monitored for signs of bleeding (hemorrhage), high blood pressure, and cardiac arrhythmias (such as atrial fibrillation). Global Supply Chain by Ernest Oncology Ernest Oncology specializes in the bulk distribution of Ibrutinib 140 mg across the Middle East (UAE, Riyadh), Africa (South Africa, Nigeria), and Asia-Pacific (Singapore, Australia). Direct Indian Export: Leveraging India’s pharmaceutical manufacturing strength to provide cost-effective oncology solutions. Bulk Supplier Capacity: We cater to hospital tenders and large-scale pharmacy distributors in Europe and the USA. Cold-Chain Integrity: Our logistics partners ensure that temperature-sensitive oncology meds reach Sydney or London without compromising efficacy. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

The Ultimate Guide to Tagrisso (Osimertinib) 80 mg: Uses, Benefits, and Global Supply In the evolving landscape of precision medicine, Tagrisso (Osimertinib) 80 mg has emerged as a gold-standard treatment for specific types of lung cancer. For patients and healthcare providers in Washington (USA), London (UK), Riyadh (Saudi Arabia), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), accessing this life-saving medication reliably is a top priority. What is Tagrisso (Osimertinib) 80 mg? Tagrisso, containing the active ingredient Osimertinib, is a third-generation Tyrosine Kinase Inhibitor (TKI). It is specifically designed to target and block the Epidermal Growth Factor Receptor (EGFR) mutations that drive the growth of cancer cells. Common Side Effects While Tagrisso is better tolerated than traditional chemotherapy, patients may experience: Diarrhea and nausea Skin rash or dry skin Nail inflammation (paronychia) Fatigue or decreased appetite Product Specifications: Tagrisso (Osimertinib) 80 mg Active Ingredient and Composition Each film-coated tablet contains 80 mg of Osimertinib (as mesylate). It is a third-generation, irreversible Tyrosine Kinase Inhibitor (TKI) designed to target specific mutations in the Epidermal Growth Factor Receptor (EGFR). Therapeutic Class and Category Tagrisso is classified as an Antineoplastic agent, specifically under the class of Protein Kinase Inhibitors. It is a targeted therapy, not a traditional chemotherapy. Mechanism of Action Osimertinib works by binding to certain mutant forms of EGFR (including T790M, L858R, and exon 19 deletion) which are prevalent in non-small cell lung cancer. By blocking these signals, the medication inhibits tumor cell proliferation and survival. It is notably effective due to its ability to cross the blood-brain barrier, making it vital for patients with CNS metastases. Storage and Shelf Life The medication should be stored at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F), though excursions are permitted up to 30°C. It must be kept in its original blister packaging to protect the tablets from moisture and light. The standard shelf life for the product is 36 months (3 years) from the date of manufacture. Packaging and Appearance The 80 mg tablets are typically beige, oval, and film-coated, often debossed with “AZ 80“ on one side. They are usually supplied in strips or bottles of 10 or 30 tablets. Usage Guidelines and Administration Primary Indications Tagrisso 80 mg is indicated for the treatment of adult patients with: Adjuvant Therapy: Treatment after complete tumor resection in patients with EGFR mutation-positive (Exon 19 del or Exon 21 L858R) non-small cell lung cancer (NSCLC). First-Line Treatment: For metastatic NSCLC with specific EGFR mutations. Previously Treated NSCLC: For patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed during or after other EGFR TKI therapies. Recommended Dosage The standard prescribed dose is one 80 mg tablet taken orally once daily. Treatment should continue until the disease progresses or the patient experiences unacceptable toxicity. How to Administer Tablets should be swallowed whole with a glass of water. They can be taken with or without food. It is recommended to take the dose at the same time every day to maintain consistent medicine levels in the bloodstream. Do not crush, split, or chew the tablets. Special Administration (For Swallowing Difficulties) If a patient is unable to swallow the tablet whole, it can be dispersed in approximately 60 mL (2 ounces) of non-carbonated water. Stir the tablet until it is in small pieces (it will not dissolve completely) and swallow the liquid immediately. Rinse the container with an additional 120 mL to 240 mL of water and drink to ensure the full dose is consumed. Missed Dose Protocol If a dose is missed, it should be taken as soon as remembered unless the next scheduled dose is due within 12 hours. If the next dose is less than 12 hours away, the patient should skip the missed dose and resume the regular schedule. Do not take two doses at once to make up for a missed one. Safety Precautions Patients should undergo an EGFR mutation test before starting therapy. Monitoring for heart function (LVEF) and lung symptoms is advised. Women of childbearing age should use effective contraception during treatment and for 6 weeks after the final dose; men should use it for 4 months after the last dose. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

Darzalex Faspro 1800mg (Daratumumab) Liquid for Injection Darzalex Faspro 1800 mg Injection contains Daratumumab, a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Daratumumab is an immunotherapy medicine that helps the immune system identify and destroy cancer cells. Darzalex Faspro is a subcutaneous formulation of Daratumumab combined with hyaluronidase, allowing faster administration compared to traditional intravenous infusions. Ernest Oncology supplies Darzalex Faspro 1800mg (Daratumumab) Liquid for Injection globally with secure packaging, competitive export pricing, and reliable worldwide delivery. Product Information (Text Format) Product Name: Darzalex Faspro Injection Generic Name: Daratumumab Strength: 1800mg Dosage Form: Liquid for Injection Therapeutic Class: Anti-Cancer / Immunotherapy / Monoclonal Antibody Packaging Type: Vial Route of Administration: Subcutaneous Injection Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Darzalex Faspro 1800mg Injection Darzalex Faspro (Daratumumab) Injection is used in the treatment of: • Multiple Myeloma • Relapsed or Refractory Multiple Myeloma • Newly Diagnosed Multiple Myeloma (in combination therapy) It is commonly used together with other anticancer medicines such as lenalidomide, bortezomib, or dexamethasone. How Darzalex Faspro Injection Works Daratumumab works by targeting the CD38 protein found on multiple myeloma cells. By binding to this protein, the medicine helps the immune system recognize and destroy cancer cells. Administration Darzalex Faspro 1800mg Injection should only be administered by a qualified healthcare professional. • Administered subcutaneously (under the skin) • Injection usually takes 3–5 minutes • Treatment schedule depends on the patient’s treatment plan and response Possible Side Effects Some patients may experience: • Fatigue • Nausea • Injection site reactions • Low blood cell counts • Fever • Increased risk of infections Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store at 2°C – 8°C (Refrigerated) • Do not freeze • Protect from light • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier 🌐 Websites www.oncologymedicinesupplier.com www.ernestvision.com www.ernestimpex.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Yervoy 50 mg/10 ml (Ipilimumab) Injection Yervoy 50 mg/10 ml Injection contains Ipilimumab, an advanced immunotherapy medicine used in the treatment of several types of cancers. Ipilimumab belongs to the class of medicines known as monoclonal antibodies and works by stimulating the immune system to recognize and attack cancer cells. Ipilimumab works by blocking the CTLA-4 protein, which normally suppresses immune responses. By inhibiting this protein, the medicine helps activate immune cells that can target and destroy cancer cells. Ernest Oncology supplies Yervoy 50mg/10ml (Ipilimumab) Injection worldwide with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Yervoy Injection Generic Name: Ipilimumab Strength: 50 mg/10 ml Dosage Form: Injection Therapeutic Class: Anti-Cancer / Immunotherapy / Monoclonal Antibody Packaging Type: Vial Route of Administration: Intravenous (IV) Infusion Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Yervoy 50 mg/10 ml Injection Yervoy (Ipilimumab) Injection is used in the treatment of: • Melanoma (Skin Cancer) • Non-Small Cell Lung Cancer (NSCLC) • Kidney Cancer (Renal Cell Carcinoma) • Colorectal Cancer • Liver Cancer (Hepatocellular Carcinoma) It is often used alone or in combination with other immunotherapy medicines such as Nivolumab. How Yervoy Injection Works Ipilimumab works by blocking the CTLA-4 protein on T-cells, which enhances the immune system’s ability to detect and destroy cancer cells. This process helps improve the body’s immune response against tumors. Administration Yervoy 50 mg/10 ml Injection should only be administered by a qualified healthcare professional. • Given through intravenous (IV) infusion • Usually administered every 3 weeks depending on treatment protocol • Administered in hospitals or oncology treatment centers Possible Side Effects Some patients may experience: • Fatigue • Skin rash or itching • Diarrhea • Nausea • Fever • Immune-related inflammation in organs Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store at 2°C – 8°C (Refrigerated) • Do not freeze • Protect from light • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Keytruda 100mg/4ml (Pembrolizumab) Injection Keytruda 100 mg/4 ml Injection contains Pembrolizumab, an advanced immunotherapy medicine used in the treatment of multiple types of cancer. Pembrolizumab belongs to the class of medicines known as PD-1 inhibitors (programmed death receptor-1 inhibitors), which help the immune system recognize and attack cancer cells. Pembrolizumab works by blocking the PD-1 pathway that tumors use to hide from the immune system, allowing the body’s immune cells to detect and destroy cancer cells more effectively. Ernest Oncology supplies Keytruda 100mg/4ml (Pembrolizumab) Injection globally with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Keytruda Injection Generic Name: Pembrolizumab Strength: 100mg/4ml Dosage Form: Injection Therapeutic Class: Anti-Cancer / Immunotherapy / Monoclonal Antibody Packaging Type: Vial Route of Administration: Intravenous (IV) Infusion Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Keytruda 100 mg/4 ml Injection Keytruda (Pembrolizumab) injection is used in the treatment of: • Non-Small Cell Lung Cancer (NSCLC) • Melanoma (Skin Cancer) • Head and Neck Cancer • Hodgkin Lymphoma • Cervical Cancer • Gastric Cancer • Urothelial Cancer • Triple-Negative Breast Cancer It is widely used as immunotherapy to boost the immune system’s ability to fight cancer. How Keytruda Injection Works Pembrolizumab works by blocking the PD-1 protein on immune cells, preventing cancer cells from turning off the immune response. This allows the immune system to identify and attack cancer cells more effectively. Administration Keytruda 100 mg/4 ml injection should only be administered by a qualified healthcare professional. • Given through intravenous infusion (IV) • Usually administered every 3 to 6 weeks depending on treatment protocol • Administered in hospitals or oncology treatment centers Possible Side Effects Some patients may experience: • Fatigue • Skin rash • Diarrhea • Nausea • Fever • Immune-related inflammation in organs Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store at 2°C – 8°C (Refrigerated) • Do not freeze • Protect from light • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Nilotinib Capsules 200mg Nilotinib 200 mg Capsules contain Nilotinib, a targeted anticancer medicine used in the treatment of chronic myeloid leukemia (CML). Nilotinib belongs to the class of medicines known as tyrosine kinase inhibitors, which work by blocking abnormal proteins responsible for the growth of leukemia cells. This medicine helps slow or stop the growth of cancer cells in patients with Philadelphia chromosome-positive CML and is typically prescribed when other treatments are not suitable or effective. Ernest Oncology supplies Nilotinib 200 mg capsules globally with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Nilotinib Capsules Generic Name: Nilotinib Strength: 200mg Dosage Form: Capsule Therapeutic Class: Anti-Cancer / Tyrosine Kinase Inhibitor Packaging Type: Capsule Bottle / Box Route of Administration: Oral Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Nilotinib 200mg Capsules Nilotinib capsules are used in the treatment of: • Chronic Myeloid Leukemia (CML) • Philadelphia Chromosome-Positive CML • Patients resistant or intolerant to previous leukemia therapy The medicine helps control the growth of leukemia cells and slows disease progression. How Nilotinib Capsules Work Nilotinib works by blocking the BCR-ABL tyrosine kinase protein, which is responsible for abnormal cell growth in leukemia. By inhibiting this protein, the medicine prevents the multiplication of cancer cells. Administration Nilotinib 200 mg capsules should be taken: • As prescribed by a qualified healthcare professional • Usually twice daily • Taken on an empty stomach • Swallowed whole with water Dosage and treatment duration depend on the patient’s condition and response to therapy. Possible Side Effects Some patients may experience: • Nausea • Headache • Fatigue • Skin rash • Abdominal discomfort • Changes in blood counts Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store below 25°C • Keep in a cool and dry place • Protect from moisture and sunlight • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestvision.com www.ernestimpex.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Nilotinib Capsules 150mg Nilotinib 150 mg Capsules contain Nilotinib, a targeted anticancer medicine used in the treatment of chronic myeloid leukemia (CML). Nilotinib belongs to the class of medicines known as tyrosine kinase inhibitors, which work by blocking abnormal proteins that signal cancer cells to grow and divide. This medicine helps slow or stop the growth of leukemia cells and is commonly prescribed for patients with Philadelphia chromosome-positive CML. Ernest Oncology supplies Nilotinib 150mg Capsules worldwide with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Nilotinib Capsules Generic Name: Nilotinib Strength: 150mg Dosage Form: Capsule Therapeutic Class: Anti-Cancer / Tyrosine Kinase Inhibitor Packaging Type: Capsule Bottle / Box Route of Administration: Oral Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Nilotinib 150mg Capsules Nilotinib capsules are used in the treatment of: • Chronic Myeloid Leukemia (CML) • Philadelphia Chromosome-Positive CML • Patients resistant or intolerant to previous leukemia therapy The medicine helps control the growth of leukemia cells in the body. How Nilotinib Capsules Work Nilotinib works by blocking the BCR-ABL tyrosine kinase protein, which is responsible for the uncontrolled growth of leukemia cells. By inhibiting this protein, the medicine slows down or stops the progression of leukemia. Administration Nilotinib 150 mg Capsules should be taken: • As prescribed by a qualified healthcare professional • Usually twice daily • Taken on an empty stomach • Swallowed whole with water Dosage and duration depend on the patient’s condition and treatment response. Possible Side Effects Some patients may experience: • Nausea • Headache • Fatigue • Rash • Abdominal pain • Changes in blood counts Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store below 25°C • Keep in a cool and dry place • Protect from moisture and sunlight • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestvision.com www.ernestimpex.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383